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Introduction
Although accounting for only 0.1% of all gastric can-
cers, gastric small cell carcinoma (SCC) is extremely
aggressive and spreads systemically even at an early clin-
ical stage.1–3 The prognosis is poor.2–5 Most patients die
within 1 year, and effective therapy is still lacking.4–8
Due to the similarity of biological characteristics of gas-
tric and pulmonary SCC, chemotherapy regimens spe-
cific for pulmonary SCC have been proposed for
treatment of gastric SCC, but the experience is still
rare.9–11 In this report, we present a patient with pri-
mary gastric SCC who underwent surgery and had
remarkable response to the palliative chemotherapy 
specific for pulmonary SCC.
Case Report
A 44-year-old man was admitted to Taipei Veterans
General Hospital on May 28, 2006 due to intermit-
tent epigastralgia for 2 months. His past clinical his-
tory and family history were noncontributory. The
physical examination was not remarkable. On admis-
sion, serum levels of α-fetoprotein, carcinoembryonic
antigen and cancer antigen 19-9 were all normal.
Upper gastrointestinal endoscopy done at another
local hospital revealed an ulcerative tumor, approxi-
mately 5 cm in diameter, located on the lesser curvature
side of the cardia near the esophagogastric junction.
The histological report revealed adenocarcinoma.
Computed tomography (CT) revealed a mass over the
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lesser curvature and some enlarged locoregional lymph
nodes. Chest CT did not detect any lung metastasis.
Radical total gastrectomy, modified D2 lymph node dis-
section, Roux-en-Y esophagojejunostomy and splenec-
tomy were performed on May 30, 2006. Intraoperative
cytological examination of peritoneal washings was
negative for malignancy. Macroscopically, the resected
specimen showed an ulcerative tumor measuring 80 ×
50 mm, with invasion to the esophagus (Figure 1).
Microscopically, the tumor had hyperchromatic cells
with little cytoplasm in a nest and sheet arrangement.
The tumor invaded the gastric serosal layer. Lym-
phovascular tumor emboli and perineural invasion were
also observed. Immunohistochemically, the tumor cells
were positive for synaptophysin, chromogranin A, and
CD56 (Figure 2). Primary gastric SCC was diagnosed.
The AJCC (American Joint Committee on Cancer)
stage was T3N2M0, stage IIIB.
The postoperative course was complicated by
hypovolemic shock due to bleeding from the splenic
artery, wound infection and intra-abdominal abscess.
It took more than 2 months to overcome these
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Figure 2. (A) Microscopic findings of the gastric tumor (hematoxylin & eosin, 400×). The tumor cells were also positive for: (B) CD56;
(C) synaptophysin; (D) chromogranin A.
Figure 1. Macroscopic findings of the resected stomach: an ulcera-
tive tumor measuring 80 × 50 mm, with invasion to the esophagus.
episodes. Follow-up CT (Figures 3A and 3B) in August
2006 revealed multiple enlarged lymph nodes in the
aortocaval region and hepatic hilum. The tumor
extended along the liver surface, from the subphrenic
region and falciform ligament to the right portal
region and bare area. Chemotherapy consisting of cis-
platin 80 mg/m2 on day 1 combined with etoposide
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80 mg/m2 on days 1–3 every 28 days for 12 courses
was administered.11
CT scan (Figures 3C and 3D) in November 2006
revealed remarkable reduction of the tumor along the
liver surface and of the lymph node metastases (partial
response according to RECIST [Response Evaluation
Criteria In Solid Tumors]). The chemotherapy was
well tolerated, and no major toxicity was observed.
The disease remained under control until CT in June
2007 revealed progression of lymph node metastases
and peritoneal seeding. Second-line chemotherapy was
given, with a regimen of intravenous ifosfamide at
1,000 mg/m2 with equidose mesna as a 30-minute
infusion, followed by 50 mg oral etoposide daily for
10 days.12 Therapy was repeated every 3 weeks for 3
courses. The disease progressed relentlessly and the
patient died in October 2007.
Discussion
Primary gastric SCC, first reported in 1976, is ex-
tremely rare and accounts for only 0.1% of all gastric
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Figure 3. Abdominal computed tomography scans: (A, B) before and (C, D) 3 months after chemotherapy. (A) Hepatic hilar nodes (long
arrows) and left hilar fissure node (short arrow). (B) Aortocaval and retrocaval nodes and tumor seeding over the right subhepatic region
(arrow). (C) and (D) show remarkable reduction of the tumor along the liver surface and of the lymph node metastases.
carcinoma.1 Even in all gastrointestinal SCC, gastric
SCC represents only 11%.13 Primary gastric SCC is also
rare in Japan, where the incidence of gastric adeno-
carcinoma is much higher than in Western countries.
Kusayanagi et al reviewed previous literature from 1976
to July 2001, which yielded only 37 cases.6 Of them,
89% (33 cases) were Japanese and 11% (4 cases) were
from Western countries.
The histological features of gastric SCC are similar
to those of pulmonary SCC, demonstrating very scanty
cytoplasm, small-sized oval nuclei, and multiple mitotic
figures.4 Microscopically, gastric SCC is divided into
2 types: a pure type and a composite type consisting of
glandular and/or squamous differentiation.7 The pure
type was more common (60%) in previous reports.5,6,8
Han et al hypothesized that the histologically different
components of the composite type originated from the
same progenitor cell, which was supported by P53 and
K-ras mutational analysis.14
Gastric SCC is difficult to diagnose preoperatively,
as observed in this patient. Most patients are diagnosed
as having undifferentiated adenocarcinoma, common
types of gastric adenocarcinoma or even lymphoma
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until the pathology of the resected stomach demon-
strates SCC.4,6,15–17 In 1 study, only 40% of patients
were diagnosed correctly before surgery.6 The rea-
sons may be that histological heterogeneity is com-
mon and biopsy specimens of mucosa tend to contain
only normal tissue because SCC is located mainly in the
submucosa. Immunohistochemical examination is very
valuable for the diagnosis of gastric SCC. Gastric SCC,
which shares immunohistochemical similarity with
lung SCC, is distinct for its positive reaction to chro-
mogranin-A, synaptophysin, neuron-specific enolase,
CD56 and S-100 protein as well as presence of neu-
rosecretory granules.5,13,18
Bone marrow biopsy is an important staging proce-
dure for small cell lung cancer, and most authors also rec-
ommend using staging studies similar to pulmonary SCC
for extrapulmonary SCC.19 In this patient, the initial
pathological report at another local hospital was adeno-
carcinoma. So bone marrow biopsy was not performed
and the patient received surgery directly. Follow-up
CT showed the tumor to be extensive disease, and fur-
ther bone marrow biopsy was not performed.
Gastric SCC is as clinically aggressive as lung SCC
and has a poor prognosis, with a median survival of 
7 months.2–5 When diagnosed, gastric SCC shows a
high incidence of vasculolymphatic invasion, marked
deep infiltration and distant metastases.2,3 In 1 re-
view, 63% (24/38) of patients died within 1 year of
being diagnosed with gastric SCC.6
The standard treatment for gastric SCC has not
been established. Operation and/or postoperative che-
motherapy were used in most of the studies, but the
results were not satisfactory.3–4,16–18 Because of the
similarity of clinical and biological characteristics
shared by gastric and pulmonary SCC, O’Byrne et al
reported that chemotherapy with cyclophosphamide,
doxorubicin, and etoposide was effective,9 while
Shimada et al reported that TS-1 and cisplatin were
useful,10 as opposed to the conventional chemotherapy
regimens such as 5-fluorouracil and mitomycin for
gastric adenocarcinoma. The most commonly used
combination chemotherapy regimen for patients with
extensive-stage lung SCC is etoposide and cisplatin.20
Futagami et al reported a case of gastric SCC with
multiple liver and lung metastases who was success-
fully treated with cisplatin and etoposide.11 Accord-
ingly, we used chemotherapy with cisplatin 80 mg/m2
on day 1 combined with etoposide 80 mg/m2 on
days 1–3 every 28 days. After 3 months of treatment,
the reduction in metastases was remarkable and the
disease was under good control for 10 months. The
duration of response was 7 months, and progression-
free survival was 10 months in this patient. According
to previous reports, most patients die within 1 year of
being diagnosed with gastric SCC,2–8 while our
patient survived for 17 months. The patient tolerated
the chemotherapy well and no major side effects were
observed. His quality of life was satisfactory.
In conclusion, although a standard treatment for
gastric SCC has not been established, intensive che-
motherapy should be considered to promote long-
term survival, and chemotherapy with cisplatin and
etoposide is effective in the treatment of primary gas-
tric SCC. Larger trials are needed to further prove the
efficacy of this regimen and to determine the best treat-
ment for gastric SCC.
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